Research

The goal of the Ho Lab is to develop novel therapeutics for pediatric brain tumors and translate bench work to clinical trials.

Cancer intrinsic mechanisms that mediate immune evasion in pediatric brain cancer and glioblastoma

We are currently developing a novel immunotherapy to enhance immunogenicity of pediatric brain tumors including DIPG and medulloblastoma as well as adult glioblastoma to sensitize to immune checkpoint blockade.

Learn More >

Regulation of Senescence in p53 mutant medulloblastoma

We are investigating novel therapies to target medulloblastoma by regulating senescence pathway in p53 mutant medulloblastoma with the worst prognosis.

Learn more >

PP2A as a novel immunotherapy target

We identified the role of PP2A in mediating tumor response and are currently developing novel therapeutics targeting this enzyme.

Learn more >